scholarly journals Rethinking the role of myeloid-derived suppressor cells in adoptive T-cell therapy for cancer

2014 ◽  
Vol 3 (4) ◽  
pp. e28464 ◽  
Author(s):  
Ainhoa Arina
Keyword(s):  
T Cell ◽  
Cell Therapy ◽  
Suppressor Cells ◽  
Adoptive T Cell Therapy ◽  
Myeloid Derived Suppressor Cells ◽  
T Cell Therapy

scholarly journals Monocytic Myeloid-Derived Suppressor Cells Underpin Resistance to Adoptive T Cell Therapy in Nasopharyngeal Carcinoma

2020 ◽  
Author(s):  
Richard Hopkins ◽  
Wenwei Xiang ◽  
Damien Marlier ◽  
Veonice Bijin Au ◽  
Qianting Ching ◽  
...  
Keyword(s):  
T Cell ◽  
Nasopharyngeal Carcinoma ◽  
Cell Therapy ◽  
Suppressor Cells ◽  
Adoptive T Cell Therapy ◽  
Myeloid Derived Suppressor Cells ◽  
T Cell Therapy

scholarly journals Myeloid-Derived Suppressor Cells: Implications in the Resistance of Malignant Tumors to T Cell-Based Immunotherapy

2021 ◽  
Vol 9 ◽  
Author(s):  
Houhui Shi ◽  
Kai Li ◽  
Yanghong Ni ◽  
Xiao Liang ◽  
Xia Zhao
Keyword(s):  
T Cell ◽  
Cancer Patients ◽  
Oncolytic Virus ◽  
Malignant Tumors ◽  
Checkpoint Inhibitors ◽  
Suppressor Cells ◽  
Immunological Response ◽  
Adoptive T Cell Therapy ◽  
Myeloid Derived Suppressor Cells ◽  
T Cell Therapy

T lymphocytes function as major players in antigen-mediated cytotoxicity and have become powerful tools for exploiting the immune system in tumor elimination. Several types of T cell-based immunotherapies have been prescribed to cancer patients with durable immunological response. Such strategies include immune checkpoint inhibitors, adoptive T cell therapy, cancer vaccines, oncolytic virus, and modulatory cytokines. However, the majority of cancer patients still failed to take the advantage of these kinds of treatments. Currently, extensive attempts are being made to uncover the potential mechanism of immunotherapy resistance, and myeloid-derived suppressor cells (MDSCs) have been identified as one of vital interpretable factors. Here, we discuss the immunosuppressive mechanism of MDSCs and their contributions to failures of T cell-based immunotherapy. Additionally, we summarize combination therapies to ameliorate the efficacy of T cell-based immunotherapy.

scholarly journals Redirecting the Immune Response: Role of Adoptive T Cell Therapy

2010 ◽  
Vol 21 (5) ◽  
pp. 533-541 ◽  
Author(s):  
Anna Mondino ◽  
Valérie Dardalhon ◽  
Rodrigo Hess Michelini ◽  
Severine Loisel-Meyer ◽  
Naomi Taylor
Keyword(s):  
Immune Response ◽  
T Cell ◽  
Cell Therapy ◽  
Adoptive T Cell Therapy ◽  
T Cell Therapy

scholarly journals 'Off-the-shelf’ allogeneic antigen-specific adoptive T-cell therapy for the treatment of multiple EBV-associated malignancies

2021 ◽  
Vol 9 (2) ◽  
pp. e001608
Author(s):  
Debottam Sinha ◽  
Sriganesh Srihari ◽  
Kirrliee Beckett ◽  
Laetitia Le Texier ◽  
Matthew Solomon ◽  
...  
Keyword(s):  
T Cell ◽  
Cell Therapy ◽  
Adoptive T Cell Therapy ◽  
Nuclear Antigen ◽  
T Cell Therapy ◽  
In Vivo Models ◽  
Hla Alleles ◽  
Cell Therapies ◽  
Wide Range

BackgroundEpstein-Barr virus (EBV), an oncogenic human gammaherpesvirus, is associated with a wide range of human malignancies of epithelial and B-cell origin. Recent studies have demonstrated promising safety and clinical efficacy of allogeneic ‘off-the-shelf’ virus-specific T-cell therapies for post-transplant viral complications.MethodsTaking a clue from these studies, we developed a highly efficient EBV-specific T-cell expansion process using a replication-deficient AdE1-LMPpoly vector that specifically targets EBV-encoded nuclear antigen 1 (EBNA1) and latent membrane proteins 1 and 2 (LMP1 and LMP2), expressed in latency II malignancies.ResultsThese allogeneic EBV-specific T cells efficiently recognized human leukocyte antigen (HLA)-matched EBNA1-expressing and/or LMP1 and LMP2-expressing malignant cells and demonstrated therapeutic potential in a number of in vivo models, including EBV lymphomas that emerged spontaneously in humanized mice following EBV infection. Interestingly, we were able to override resistance to T-cell therapy in vivo using a ‘restriction-switching’ approach, through sequential infusion of two different allogeneic T-cell therapies restricted through different HLA alleles. Furthermore, we have shown that inhibition of the programmed cell death protein-1/programmed death-ligand 1 axis in combination with EBV-specific T-cell therapy significantly improved overall survival of tumor-bearing mice when compared with monotherapy.ConclusionThese findings suggest that restriction switching by sequential infusion of allogeneic T-cell therapies that target EBV through distinct HLA alleles may improve clinical response.

Sign in / Sign up

Export Citation Format

Share Document